0       0

AST 2014 - Cutting Edge of Transplantation


FR02a - Regulatory T Cells: Ready and Useful... or Lost in Translation?


Feb 14, 2014 10:30am ‐ Feb 14, 2014 11:00am

Description

Progress in terms of ex vivo preparation of Tregs including obtaining sufficient amplification; purity/activity has finally made this approach feasible. Trials in autoimmune disease (Bluestone), and approaches for trials in transplantation are underway, as well as in GVHD/BMT (Blazar). In non-lymphopenic settings such as transplantation, how can we deal with the effector response and tip the balance towards Tregs if most IS agents inhibit Tregs?

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content